Results from Celtaxsys’ Acebilustat Phase 2 Trial in Cystic Fibrosis Patients Showing Clinically Meaningful Improvement in Pulmonary Exacerbations Presented at the North American Cystic Fibrosis Conference   ATLANTA, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Celtaxsys, Inc., a clinical stage pharmaceutical development company focused on advancing treatments for patients with rare inflammatory diseases, today...

Data from Celtaxsys’ Acebilustat Phase 2 Trial addressing Lung Inflammation in CF Patients to be presented at the North American Cystic Fibrosis Conference ATLANTA, Oct. 11, 2018 (GLOBE NEWSWIRE) -- Full results from the recently completed Phase 2 trial (EMPIRE-CF) of Celtaxsys’ acebilustat will be presented at the North American Cystic Fibrosis...

Celtaxsys Announces Results of Phase 2 Trial Showing Clinically Meaningful Improvement in Pulmonary Exacerbations in Cystic Fibrosis Patients -Acebilustat is the first novel anti-inflammatory molecule evidencing the potential to reduce frequency of pulmonary exacerbations and prolong time to first exacerbation in CF patients  --Celtaxsys,...

Celtaxsys Announces Last Patient, Last Visit in Landmark CF Phase 2b Lung Function Preservation Trial, Clinical Results Expected in July ATLANTA, May 17, 2018 (GLOBE NEWSWIRE) -- Celtaxsys, Inc., a clinical stage pharmaceutical development company focused on advancing treatments for patients with rare inflammatory diseases, today...

Celtaxsys announces the issue of four new patents expanding its pipeline of selective leukotriene B4 modulation anti-inflammatory medicines New patents build on previously granted composition of matter protection for acebilustat, with additional intellectual protection for use in cystic fibrosis, as well as new compositions for second...